UCB
UCB
1,12 %
71,98 EUR
0,80
Kurs
71,98
Hög
71,98
Förändring
1,12 %
Låg
70,70
Uppdaterad
2019-06-19
Öppen
71,38
Factsheet for UCB
Company Profile
Description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).
Key Stats
Website: http://www.ucb.com
Headquarter country: Belgium
Employees: 7 563
Market Cap (at close 18-06-2019): EUR 13B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 15,40 18,70 34,20 73,70 41,60
Forward Price/Earnings 15,20 14,20 16,60 37,70 24,00
Price/Free Cash Flow 19,00 20,00 137,60 51,30 66,20
Return on Assets 7,80 7,50 4,90 5,90 2,10
Return on Equity 13,20 13,20 9,20 11,70 4,40
Return on Invested Capital 11,00 10,80 7,40 9,10 4,10
Dividend


Dividend/Share:1,20
Ex. Dividend Date:2018-12-31
Trailing Dividend Yield:1,70
Payout Ratio:28,10
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 4 632,00 4 530,00 4 178,00 3 876,00 3 344,00
Gross Profit 3,43 3,33 2,98 2,72 2,29
Gross Margin % 74,14% 73,51% 71,23% 70,15% 68,51%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 1 365,00 1 278,00 1 083,00 762,00 476,00
Net income 800,00 753,00 520,00 623,00 209,00
Basic Earnings Per Share 4,24 4,00 2,76 3,25 1,10
Operating Income 1,10 1,12 0,92 0,64 0,37
Operating Margin % 23,83% 24,61% 22,04% 16,46% 11,00%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 1 089,00 927,00 427,00 245,00 512,00
Capital Expenditures -341,00 -209,00 -138,00 -146,00 -161,00
Free Cash Flow 748,00 718,00 289,00 99,00 351,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 2 950,00 2 677,00 2 331,00 2 838,00 2 501,00 2 421,00
Long Term Assets 7 564,00 7 240,00 7 881,00 8 118,00 7 647,00 7 486,00
Total Assets 10 514,00 9 917,00 10 212,00 10 956,00 10 148,00 9 907,00
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 2 238,00 1 949,00 2 418,00 3 061,00 2 336,00 2 336,00
Long Term Liabilities 2 155,00 2 210,00 2 223,00
Total Liabilities 4 104,00 4 628,00 5 284,00
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings 4 394,00 3 811,00 3 263,00 2 915,00 2 515,00 2 660,00
Treasury Stock 342,00 357,00 283,00 295,00 173,00 168,00
Total Stockholder Equity 6 310,00 5 813,00 5 584,00 5 672,00 5 002,00 4 603,00
Net Tangible Assets 470,00 158,00 -469,00 -547,00 -1 099,00 -1 553,00